Tetra Pharm Technologies ApS
CVR 40738223 · Private limited company (ApS) · Active · Low risk
Tetra Pharm Technologies ApS is a Private limited company (ApS), founded on , based in København S. The company is registered in the industry fremstilling af farmaceutiske præparater. Our model estimates a bankruptcy risk of 1.0% over the next 12 months, which is 0.7 times the average for Danish companies. 6 annual reports have been published, of which 6 more than six months after the end of the financial year. The latest annual report (31 Dec 2025) shows equity of DKK -25.8m and a net result of DKK -52.6m. CEO: Ulrich Wulff Norden Venge, Rolf Sass Sørensen.
Bankruptcy risk for Tetra Pharm Technologies ApS
0.7 × the average (1.41%) · higher risk than 72% of active Danish companies
Increases the risk
Reduces the risk
The factors show how often companies with the same characteristic went bankrupt compared with the average (“lift”). The risk is a statistical estimate from a model trained on 141,000+ Danish bankruptcies (AUC 0.93) – not a credit rating. Read about the method.
Company details
- CVR number
- 40738223
- Status
- Active
- Company type
- Private limited company (ApS)
- Founded
- (7 years)
- Address
- c/o Tetra Pharm, Ørestads Boulevard 108
2300 København S - Municipality
- København
- Industry
- Fremstilling af farmaceutiske præparater (212000)
Bankruptcies in the industry: Fremstilling af farmaceutiske præparater - Share capital
- DKK 75k
- Auditor
- MARTINSEN STATSAUTORISERET REVISIONSPARTNERSELSKAB
- Audit opted out
- No
Warning signs
| Annual reports filed late | 6 of 6 |
| Missing annual report | No |
| Negative equity | Yes |
| Equity ratio | -114.5% |
| Current ratio | 147% |
| Moves (last 2 years) | 1 |
| CEO changes in total | 5 |
| CEO's previous bankruptcies | 0 |
| Other companies at the address | 18 |
| Going-concern uncertainty | Yes |
Financials and key figures
| Financial year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Gross profit | DKK -17.7m | DKK 1.5m | DKK 585k |
| Net profit | DKK -52.6m | DKK -55.2m | DKK -32.9m |
| Equity | DKK -25.8m | DKK 26.7m | DKK 32.1m |
| Total assets | DKK 22.6m | DKK 31.3m | DKK 34.6m |
| Cash | DKK 5.4m | DKK 3.9m | – |
| Short-term debt | DKK 9.4m | DKK 4.5m | – |
| Avg. employees | 47 | 37 | – |
Latest annual report: Reporting class B · auditor's statement: Revisionspåtegning · Martinsen, Statsautoriseret Revisionspartnerselskab.
Filed annual reports
| Reporting period | Published | Days after period end | |
|---|---|---|---|
| 1 Jan 2025 – 31 Dec 2025 | 196 | Late | |
| 1 Jan 2024 – 31 Dec 2024 | 189 | Late | |
| 1 Jan 2023 – 31 Dec 2023 | 190 | Late | |
| 1 Jan 2022 – 31 Dec 2022 | 213 | Late | |
| 1 Jan 2021 – 31 Dec 2021 | 201 | Late | |
| 26 Aug 2019 – 31 Dec 2020 | 213 | Late |
The annual report must reach the Danish Business Authority no later than 5 months after the end of the financial year. We mark reports published more than 6 months after as “late”.
Management, owners and auditor
| Role | Name | From | To |
|---|---|---|---|
| CEO | Ulrich Wulff Norden Venge | Current | |
| CEO | Rolf Sass Sørensen | Current | |
| CEO | Martin Stefan Rose | ||
| CEO | Jesper Breum | ||
| Board | Claus Berner Nielsen | Current | |
| Board | Jesper Breum | Current | |
| Board | Søren Maarssø | Current | |
| Board | Rolf Sass Sørensen | Current | |
| Board | Per Mogens Bugge | ||
| Board | Jesper Breum | ||
| Board | Martin Stefan Rose | ||
| Board | Søren Rose | ||
| Board | Nikolay Tretiyakov | ||
| Board | Lars Frøvang Thomsen | ||
| Board | Jesper Breum | ||
| Owner (5%) | Leafy Tunnel Fund 1, L.P. | Current | |
| Owner (5%) | OLE GS HOLDING ApS | Current | |
| Owner (20%) | Breum Holding EST. 2016 ApS | Current | |
| Owner (20%) | BrainFrame ApS | Current | |
| Owner (5%) | RUMP INVEST ApS | Current | |
| Owner (25%) | Nesroht Holding ApS | Current | |
| Owner (25%) | Breum Holding EST. 2016 ApS | ||
| Owner (25%) | BrainFrame ApS | ||
| Owner (10%) | BWC Group Inc. | ||
| Owner (5%) | RUMP INVEST ApS | ||
| Owner (10%) | Nesroht Holding ApS | ||
| Owner (20%) | Nesroht Holding ApS | ||
| Auditor | MARTINSEN STATSAUTORISERET REVISIONSPARTNERSELSKAB | Current | |
| Founder | BrainFrame ApS | Current |
The CEOs' other companies
Ulrich Wulff Norden Venge – 11 other companies, of which 1 bankrupt
- Deemly ApS Bankrupt 2 Feb 2021
- CCL PeopleCo Côte d Azur ApS Active
- Copenhagen Coffee Lab ApS Active
- Copenhagen Coffee Lab Holding ApS Active
- Klemmen Espressoservice ApS Fusioneret
- Klinikdrift IVS Fusioneret
- Kliniksupport IVS Fusioneret
- SolarImpact A/S Active
- TANDLÆGERNE VENGE ApS Active
- Tetrapharm Bioengineering ApS Active
- Tetrapharm Therapeutics ApS Active
Rolf Sass Sørensen – 2 other companies
- Tetrapharm Bioengineering ApS Active
- Tetrapharm Therapeutics ApS Active
Martin Stefan Rose – 4 other companies
- BrainFrame ApS Active
- Tetrapharm Bioengineering ApS Active
- Tetrapharm Therapeutics ApS Active
- XBR Invest ApS Active
Jesper Breum – 5 other companies
- Breum Holding EST. 2016 ApS Active
- CFF Investment EST 2016 ApS Active
- Tetrapharm Bioengineering ApS Active
- Tetrapharm Therapeutics ApS Active
- XBR Invest ApS Active
Address history (2 moves)
| c/o Tetra Pharm, Ørestads Boulevard 108, 2300 København S | |
| Søndre Jernbanevej 11, 3400 Hillerød | |
| Fugleøjevej 12, 3670 Veksø Sjælland |
Other companies at the same address
- Atnahs Pharma Denmark ApS Active
- COMCARE A/S Fusioneret
- Cellnex Denmark ApS Active
- ERICSSON DANMARK A/S Active
- Finest Cask ApS Active
- Intellis A/S Active
- On Tower Denmark ApS Active
- PHILIP MORRIS ApS Active
- PIXLAB A/S Active
- Pharmanovia A/S Active
- Punktum dk A/S Active
- S. LARSEN HOLDING ApS Active
- STANDOUT A/S Active
- Standoutmedia Holding ApS Active
- TENET A/S Active
- Tetrapharm Bioengineering ApS Active
- Tetrapharm Therapeutics ApS Active
- iBridge Consulting ApS Active
Similar companies in København
- H. LUNDBECK A/S Valby
- GUNNAR KJEMS ApS København K
- Tetrapharm Therapeutics ApS København S
- Tetrapharm Bioengineering ApS København S
- Luvalis Pharma ApS Vanløse
- NeuroVersis Therapeutics ApS København K
- QuantumCell ApS København K
- Vautia Therapeutics ApS København K
- Corxel Pharmaceuticals Denmark ApS København V
- Dispersome IP ApS København Ø
- Maddox Pharma Swiss ApS København S
- Gefjon Pharma ApS København N
Questions and answers about Tetra Pharm Technologies ApS
Has Tetra Pharm Technologies ApS gone bankrupt?
No, Tetra Pharm Technologies ApS is not registered as bankrupt in the CVR register. Its status is: active.
What is the bankruptcy risk of Tetra Pharm Technologies ApS?
Our model estimates a bankruptcy risk of 1.0% over the next 12 months (low risk), which is 0.7 times the average for Danish companies.
Who is the CEO of Tetra Pharm Technologies ApS?
Ulrich Wulff Norden Venge, Rolf Sass Sørensen are the CEOs of Tetra Pharm Technologies ApS.
Who is the auditor of Tetra Pharm Technologies ApS?
Tetra Pharm Technologies ApS most recently used MARTINSEN STATSAUTORISERET REVISIONSPARTNERSELSKAB.
When was Tetra Pharm Technologies ApS founded?
Tetra Pharm Technologies ApS was founded on 26 August 2019.
What is the equity of Tetra Pharm Technologies ApS?
Equity was DKK -25.8m according to the annual report for the period ending 31 December 2025.
Source: the CVR register and annual reports published by the Danish Business Authority. The information is updated continuously.